



REPORTED SALES vs. PRIOR PERIOD (\$MM)

**CONSUMER SEGMENT <sup>(2)</sup>**

BABY CARE

	2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	\$ 111	102	8.8%	8.8%	-
Intl	400	443	-9.7%	-0.9%	-8.8%
WW	511	545	-6.2%	1.0%	-7.2%

ORAL CARE

US	158	160	-1.3%	-1.3%	-
Intl	245	251	-2.4%	8.8%	-11.2%
WW	403	411	-1.9%	5.0%	-6.9%

OTC

US	405	366	10.7%	10.7%	-
Intl	588	645	-8.8%	9.1%	-17.9%
WW	993	1,011	-1.8%	9.6%	-11.4%

SKIN CARE

US	492	457	7.7%	7.7%	-
Intl	411	457	-10.1%	1.5%	-11.6%
WW	903	914	-1.2%	4.6%	-5.8%

WOMEN'S HEALTH

US	6	24	-75.0%	-75.0%	-
Intl	281	303	-7.3%	5.5%	-12.8%
WW	287	327	-12.2%	-0.4%	-11.8%

WOUND CARE / OTHER

US	187	200	-6.5%	-6.5%	-
Intl	106	149	-28.9%	-19.7%	-9.2%
WW	293	349	-16.0%	-12.1%	-3.9%

TOTAL CONSUMER

US	1,359	1,309	3.8%	3.8%	-
Intl	2,031	2,248	-9.7%	3.1%	-12.8%
WW	\$ 3,390	3,557	-4.7%	3.4%	-8.1%

FIRST QUARTER					
	2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
	\$				
	111	102	8.8%	8.8%	-
	400	443	-9.7%	-0.9%	-8.8%
	511	545	-6.2%	1.0%	-7.2%
	158	160	-1.3%	-1.3%	-
	245	251	-2.4%	8.8%	-11.2%
	403	411	-1.9%	5.0%	-6.9%
	405	366	10.7%	10.7%	-
	588	645	-8.8%	9.1%	-17.9%
	993	1,011	-1.8%	9.6%	-11.4%
	492	457	7.7%	7.7%	-
	411	457	-10.1%	1.5%	-11.6%
	903	914	-1.2%	4.6%	-5.8%
	6	24	-75.0%	-75.0%	-
	281	303	-7.3%	5.5%	-12.8%
	287	327	-12.2%	-0.4%	-11.8%
	187	200	-6.5%	-6.5%	-
	106	149	-28.9%	-19.7%	-9.2%
	293	349	-16.0%	-12.1%	-3.9%
	1,359	1,309	3.8%	3.8%	-
	2,031	2,248	-9.7%	3.1%	-12.8%
	\$ 3,390	3,557	-4.7%	3.4%	-8.1%

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**PHARMACEUTICAL SEGMENT <sup>(2) (3)</sup>**

**IMMUNOLOGY**

	2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	\$ 1,755	1,547	13.4%	13.4%	-
Intl	708	796	-11.1%	3.1%	-14.2%
WW	2,463	2,343	5.1%	9.9%	-4.8%

**REMICADE**

US	1,055	997	5.8%	5.8%	-
US Exports <sup>(4)</sup>	181	167	8.4%	8.4%	-
Intl	364	446	-18.4%	-6.2%	-12.2%
WW	1,600	1,610	-0.6%	2.8%	-3.4%

**SIMPONI / SIMPONI ARIA**

US	155	104	49.0%	49.0%	-
Intl	145	155	-6.5%	9.7%	-16.2%
WW	300	259	15.8%	25.5%	-9.7%

**STELARA**

US	364	279	30.5%	30.5%	-
Intl	185	177	4.5%	22.5%	-18.0%
WW	549	456	20.4%	27.4%	-7.0%

**OTHER IMMUNOLOGY**

US	-	-	-	-	-
Intl	14	18	-22.2%	-13.7%	-8.5%
WW	14	18	-22.2%	-13.7%	-8.5%

**INFECTIOUS DISEASES**

US	412	561	-26.6%	-26.6%	-
Intl	563	639	-11.9%	4.2%	-16.1%
WW	975	1,200	-18.8%	-10.2%	-8.6%

**EDURANT**

US	9	5	80.0%	80.0%	-
Intl	82	76	7.9%	30.6%	-22.7%
WW	91	81	12.3%	33.6%	-21.3%

**OLYSIO / SOVRIAD**

US	98	291	-66.3%	-66.3%	-
Intl	136	63	*	*	**
WW	234	354	-33.9%	-26.2%	-7.7%

**PREZISTA / PREZCOBIX**

US	234	214	9.3%	9.3%	-
Intl	193	231	-16.5%	-1.6%	-14.9%
WW	427	445	-4.0%	3.7%	-7.7%

**OTHER INFECTIOUS DISEASES**

US	71	51	39.2%	39.2%	-
Intl	152	269	-43.5%	-34.5%	-9.0%
WW	223	320	-30.3%	-22.8%	-7.5%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**FIRST QUARTER**

**NEUROSCIENCE**

	2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	750	601	24.8%	24.8%	-
Intl	868	1,037	-16.3%	-3.2%	-13.1%
WW	<u>1,618</u>	<u>1,638</u>	-1.2%	7.1%	-8.3%

**CONCERTA / METHYLPHENIDATE**

US	126	35	*	*	-
Intl	98	115	-14.8%	-3.5%	-11.3%
WW	<u>224</u>	<u>150</u>	49.3%	58.0%	-8.7%

**INVEGA**

US	94	86	9.3%	9.3%	-
Intl	61	79	-22.8%	-8.7%	-14.1%
WW	<u>155</u>	<u>165</u>	-6.1%	0.7%	-6.8%

**INVEGA SUSTENNA / XEPLION**

US	228	182	25.3%	25.3%	-
Intl	183	191	-4.2%	12.5%	-16.7%
WW	<u>411</u>	<u>373</u>	10.2%	18.7%	-8.5%

**RISPERDAL CONSTA**

US	104	106	-1.9%	-1.9%	-
Intl	150	204	-26.5%	-13.0%	-13.5%
WW	<u>254</u>	<u>310</u>	-18.1%	-9.2%	-8.9%

**OTHER NEUROSCIENCE**

US	198	192	3.1%	3.1%	-
Intl	376	448	-16.1%	-4.5%	-11.6%
WW	<u>574</u>	<u>640</u>	-10.3%	-2.2%	-8.1%

**ONCOLOGY**

US	334	240	39.2%	39.2%	-
Intl	774	782	-1.0%	15.7%	-16.7%
WW	<u>1,108</u>	<u>1,022</u>	8.4%	21.2%	-12.8%

**IMBRUVICA**

US	66	6	*	*	-
Intl	50	4	*	*	**
WW	<u>116</u>	<u>10</u>	*	*	**

**VELCADE**

US	-	-	-	-	-
Intl	339	408	-16.9%	-4.0%	-12.9%
WW	<u>339</u>	<u>408</u>	-16.9%	-4.0%	-12.9%

**ZYTIGA**

US	253	229	10.5%	10.5%	-
Intl	303	283	7.1%	26.3%	-19.2%
WW	<u>556</u>	<u>512</u>	8.6%	19.2%	-10.6%

**OTHER ONCOLOGY**

US	15	5	*	*	-
Intl	82	87	-5.7%	10.1%	-15.8%
WW	<u>97</u>	<u>92</u>	5.4%	20.3%	-14.9%

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FIRST QUARTER				
	2015	2014	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>CARDIOVASCULAR / METABOLISM / OTHER <sup>(5)</sup></b>					
US	1,120	791	41.6%	41.6%	-
Intl	442	504	-12.3%	-0.8%	-11.5%
WW	<u>1,562</u>	<u>1,295</u>	20.6%	25.1%	-4.5%
<b>XARELTO</b>					
US	441	319	38.2%	38.2%	-
Intl	-	-	-	-	-
WW	<u>441</u>	<u>319</u>	38.2%	38.2%	0.0%
<b>INVOKANA / INVOKAMET</b>					
US	266	93	*	*	-
Intl	12	1	*	*	**
WW	<u>278</u>	<u>94</u>	*	*	**
<b>PROCIT / EPREX</b>					
US	163	176	-7.4%	-7.4%	-
Intl	106	134	-20.9%	-7.5%	-13.4%
WW	<u>269</u>	<u>310</u>	-13.2%	-7.4%	-5.8%
<b>OTHER</b>					
US	250	203	23.2%	23.2%	-
Intl	324	369	-12.2%	-1.7%	-10.5%
WW	<u>574</u>	<u>572</u>	0.3%	7.1%	-6.8%
<b>TOTAL PHARMACEUTICAL</b>					
US	4,371	3,740	16.9%	16.9%	-
Intl	3,355	3,758	-10.7%	3.7%	-14.4%
WW	<u>\$ 7,726</u>	<u>7,498</u>	3.0%	10.2%	-7.2%

**Supplemental Sales Information**

	2014				
	Q1	Q2	Q3	Q4	Full Year
<b>INVOKANA / INVOKAMET</b>					
US	93	114	169	193	569
Intl	1	3	5	8	17
WW	<u>94</u>	<u>117</u>	<u>174</u>	<u>201</u>	<u>586</u>
<b>IMBRUVICA</b>					
US	6	33	42	64	145
Intl	4	9	14	28	55
WW	<u>10</u>	<u>42</u>	<u>56</u>	<u>92</u>	<u>200</u>

See footnotes at end of schedule

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	FIRST QUARTER		% Change		
	2015	2014	Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES <sup>(2)</sup></b>					
<b>CARDIOVASCULAR CARE</b>					
US	\$ 228	205	11.2%	11.2%	-
Intl	301	336	-10.4%	3.4%	-13.8%
WW	529	541	-2.2%	6.4%	-8.6%
<b>DIABETES CARE</b>					
US	212	192	10.4%	10.4%	-
Intl	272	320	-15.0%	0.6%	-15.6%
WW	484	512	-5.5%	4.2%	-9.7%
<b>DIAGNOSTICS <sup>(6)</sup></b>					
US	-	224	**	**	-
Intl	30	219	-86.3%	-83.5%	-2.8%
WW	30	443	-93.2%	-91.8%	-1.4%
<b>ORTHOPAEDICS</b>					
US	1,309	1,292	1.3%	1.3%	-
Intl	1,019	1,129	-9.7%	2.9%	-12.6%
WW	2,328	2,421	-3.8%	2.1%	-5.9%
<b>SPECIALTY SURGERY / OTHER</b>					
US	417	417	0.0%	0.0%	-
Intl	416	457	-9.0%	3.5%	-12.5%
WW	833	874	-4.7%	1.8%	-6.5%
<b>SURGICAL CARE</b>					
US	543	539	0.7%	0.7%	-
Intl	880	969	-9.2%	3.0%	-12.2%
WW	1,423	1,508	-5.6%	2.3%	-7.9%
<b>VISION CARE</b>					
US	253	286	-11.5%	-11.5%	-
Intl	378	475	-20.4%	-7.5%	-12.9%
WW	631	761	-17.1%	-9.0%	-8.1%
<b>TOTAL MEDICAL DEVICES</b>					
US	2,962	3,155	-6.1%	-6.1%	-
Intl	3,296	3,905	-15.6%	-3.3%	-12.3%
WW	\$ 6,258	7,060	-11.4%	-4.6%	-6.8%

\* Percentage greater than 100%

\*\* Not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Previously referred to as Other

(6) Reflects Diagnostics divestiture June 30, 2014